Incannex September 2021 Quarterly Activities Report and Appendix 4C
Highlights: • Phase 2a psilocybin-assisted therapy for Generalised Anxiety Disorder clinical trial has received approval to proceed from the Monash… Read more
HTG Annual Report 2021
FY2021 Highlights Key priorities for the Group during FY2021 were to build on momentum with a new pipeline of vessel… Read more
Positive pre-IND meeting with US FDA and ethics approval to commence Phase 2a Psi-GAD clinical trial: psilocybin-assisted psychotherapy for Generalised Anxiety Disorder
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce: 1. that… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: • Cholesterol-Lowering Program advances: – New data from in vivo cholesterol study showed NYX-PCSK9i significantly increased plasma PCSK9 levels,… Read more
Incannex engages Procaps to manufacture IHL-42X soft-gel capsules in preparation for pivotal clinical trials
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more
HTG expands ecosystem with Inmarsat Global
HIGHLIGHTS: • Harvest Technology Group has signed a Memorandum of Understanding with Inmarsat Global as a development partner for Inmarsat’s… Read more
HTG strikes reseller deal with global satellite provider Speedcast
Harvest Technology Group Limited (ASX:HTG) (Company, Group, Harvest), a global leader in network optimised remote operations, is pleased to announce… Read more
HTG Investor Presentation October 2021
button id=”1″]